RNA as a Diagnostic Tool: Advances in RNA Biomarkers


Traditionally, DNA has been the primary tool for molecular diagnostics. However, recent research has shown that RNA (ribonucleic acid) offers significant potential for disease detection and health monitoring. Unlike DNA, which reflects our genetic makeup, RNA levels change based on ongoing cellular activity. This makes RNA analysis a valuable tool for identifying early signs of disease and tracking treatment effectiveness.

The Rise of RNA Biomarkers

Technological advancements have accelerated the exploration of RNA for diagnostic purposes. Techniques like RT-qPCR allow for the accurate detection of specific RNA molecules, even in very small quantities. Microarray analysis enables researchers to examine hundreds or thousands of RNA transcripts simultaneously, providing a broader view of cellular activity. The most significant development is RNA sequencing (RNA-seq). RNA-seq allows scientists to comprehensively identify and measure all RNA transcripts within a cell, including mRNA, miRNA, and lncRNA. This unbiased approach has led to the discovery of numerous novel RNA biomarkers with diagnostic potential across various diseases.

Screening process of RNAs capable of serving as biomarkers of cancers. mRNA, lncRNA, circRNA, and miRNA in circulation have stability, specificity, and sensitivity characteristics, combined with the fact that their changes occur in different cancers, making them suitable for predicting specific cancers. Sequencing of RNAs (including mRNA, lncRNA, circRNA, and miRNA) in blood samples and subsequent qualitative and quantitative analyses provides prediction, diagnosis, and prognosis information for different types of cancers.

Specific Applications in Early Disease Detection

RNA biomarkers show promise for the early detection of various cancers. For instance, researchers have identified unique miRNA patterns in blood that can distinguish cancerous from non-cancerous tissues in lung cancer patients. Similarly, lncRNAs have shown potential for the early diagnosis of colorectal cancer. Beyond cancer, RNA analysis is proving useful in detecting neurodegenerative diseases like Alzheimer's disease, where specific mRNA profiles in cerebrospinal fluid have been linked to disease progression.

Monitoring Disease and Treatment Response

RNA biomarkers offer a valuable tool for monitoring disease progression and treatment response. By tracking changes in RNA expression levels over time, clinicians can gain insights into a patient's therapeutic response and potentially adjust treatment plans for better outcomes. For example, measuring mRNA levels associated with drug resistance can inform the modification of chemotherapy regimens in cancer patients.

Differential gene expression between Response groups at day 28. (A) Heat map panel shows z-score expression data for 779 genes meeting p<0.01 and 1.25-fold expression difference at day 28 between Responders and non-Responders (n=55). Scale is −2 to 2 (blue to red). Waterfall plot shows maximal percentage reduction of the lesion that provided the expression data shown in the heat map (index lesions, n=45). Lesions with reduction of ≥20% are indicated in gold. Sample annotation track shows 'Biopsy Site' (lymph node metastatic site in gold, missing data in white). Patient annotation track shows 'Response' (Responders in gold). Gene annotation track to right of the heat map shows 'IRIS' immune-cell transcripts (lymphoid lineage in green, myeloid lineage in blue, expression in both lineages in gold). (B) Normalized enrichment scores for GSEA evaluating Hallmark gene sets in the results for differential gene expression analysis at day 28. (C) Expression values for the CTLA4, PDCD1LG2 (PDL-2) and TIGIT transcripts in 55 biopsies provided at day 28. Data are grouped by Response status. Prior TKI therapy is indicated by circles, Naïve by diamonds. P values were obtained by testing the appropriate contrast from the extended linear model. GSEA, gene set enrichment analysis; IRIS, immune response in silico; RMA, robust multiarray average; TIGIT, T cell immunoreceptor with Ig and ITIM domains; TKI, tyrosine kinase inhibitor.

Future Directions and Challenges

Despite the exciting progress, challenges remain in widely adopting RNA-based diagnostics in clinical settings. Standardizing RNA isolation and analysis protocols is essential to ensure consistent data across different laboratories. Additionally, robust validation studies are needed to confirm the clinical relevance and accuracy of novel RNA biomarkers before they can be implemented in routine diagnostics.


RNA analysis has become a powerful approach for disease detection and monitoring. With continued research and technological refinement, RNA biomarkers hold immense potential to revolutionize diagnostics, enabling earlier diagnoses, personalized treatment plans, and improved patient outcomes.

Learn more about advancements in translational biomarker identification from cell-free RNA:


in News
RNA as a Diagnostic Tool: Advances in RNA Biomarkers
Gen store May 27, 2024
Share this post
Sign in to leave a comment
RNA Aptamers: Targeted Therapeutics and Diagnostics